DelveInsight’s ‘Chronic Pain - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Chronic Pain market report provides current treatment practices, emerging drugs, Chronic Pain market share of the individual therapies, current and forecasted Chronic Pain market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Chronic Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018–2030
Chronic Pain Overview
Chronic Pain is any pain that lasts for more than three months. The pain can gradually grow worse and recur intermittently, outlasting the normal process of recovery and adversely affecting the person’s well-being. Pain is supposed to cease after damaged tissue recovers until the root cause is treated. However, for no apparent biological reason, chronic pain can continue even after injuries heal. Depending on the cause, it may last up to 6 months or even longer. However, some painful conditions may persist for years.
The most common sources of chronic pain include low back pain, headache (migraine), neuropathic pain (Neuralgia), musculoskeletal pain (Fibromyalgia), cancer pain, post-operative pain, arthritic pain (Osteoarthritis, Rheumatoid Arthritis), and others. Chronic pain can cause significant psychological and emotional trauma and often limits an individual’s ability to function fully. It is a common complaint in older adults. A person may have more than one chronic pain condition at a time. Someone may experience chronic pain long after they are injured or without any apparent cause. In some cases, more than one factor may be involved.
Chronic pain often leads to vegetative signs (e.g., lassitude, sleep disturbance, decreased appetite, loss of taste for food, weight loss, diminished libido, constipation), which develop gradually. Constant, unremitting pain may lead to depression and anxiety and interfere with almost all activities. Patients may become inactive, withdraw socially, and become preoccupied with physical health. Psychological and social impairment may be severe, causing a virtual lack of function.
Chronic Pain Diagnosis
Diagnosing chronic pain is not easy, as there are no tools to quantify pain. Diagnosis often involves a series of tests and procedures, as well as a review of symptoms and medical history. There is no way to measure pain objectively. Only the person with chronic pain can describe how much pain he or she is feeling.
A doctor will first ask questions about the symptoms and factors that trigger pain, further investigating the location of the, how long it has been going on, and whether it is sharp or dull, constant, or occurs off and on. Sometimes a patient will be asked to rate how bad the pain is by using a numerical scale and giving more details. The doctor will do a physical exam and may order additional diagnostic tests. The diagnostic tests that are useful in the diagnosis of Chronic Pain include imaging tests like x-rays, bone scans, MRI, etc., and nerve tests like Electromyography (EMG), and some more. Other than this, physical, neurological, and mental health exams, some blood tests, and urine analysis may also be used.
Chronic Pain Treatment
There are several categories of medications that are used for the treatment of chronic pain. Oral medications include those that can be taken by mouth, such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, opioid-like agents, or combinations of opioids and non-narcotic analgesics, corticosteroids, antirheumatics/immunological agents, and anticonvulsants.
Opioids are most useful are usually reserved for cases of chronic pain when other pain relievers are not effective and when the negative side effects are manageable.
Many chronic pain patients may benefit from taking anti-depressant drugs. Types of antidepressants prescribed include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and others.
Drugs approved for the treatment of chronic pain due to different indications include Emgality (galcanezumab-gnlm), Aimovig (Eptinezumab), Tarlige (Mirogabalin besylate), Aimovig (Erenumab-aooe), and Ajovy (Fremanezumab), among others.
The Chronic Pain epidemiology division provides insights about historical and current Chronic Pain patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
In the year 2020, the total prevalent case of Chronic Pain was 187,786,024 cases in the 7MM which are expected to grow during the study period, i.e., 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Chronic Pain epidemiology [segmented as Total Prevalent Cases of Chronic Pain, Total Diagnosed Cases of Chronic Pain, Age-specific Cases of Chronic Pain, Cause-specific Cases of Chronic Pain, Severity-specific Cases of Chronic Pain and Treated cases of Chronic Pain] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Estimates show that the highest cases of Chronic Pain in the 7MM were in the United States, followed by Japan, the United Kingdom, Germany, France, Italy, and Spain in the year 2020.
The drug chapter segment of the Chronic Pain report encloses the detailed analysis of Chronic Pain marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chronic Pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Chronic Pain Approved Drugs
Emgality/Galcanezumab (Elli Lilly and Company)
Emgality (Galcanezumab-gnlm) is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults. Galcanezumab-gnlm is a humanized IgG4 monoclonal antibody specific for calcitonin-gene-related peptide (CGRP) ligand. Galcanezumab-gnlm is composed of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. Emgality is already approved in the US, Europe, and Japan for adult patients and currently, the company is also looking for its potential in adolescent patients 12 to 17 Years of age with chronic migraines.
Vyepti/ Eptinezumab (Alder Biopharmaceuticals [Acquired by Lundbeck])
Lundbeck Pharmaceutical's, Vyepti (eptinezumab), is part of a new class of antibody therapies developed to prevent migraine attacks before they start. These drugs block calcitonin gene-related peptide (CGRP), a protein associated with the onset of migraine pain. Eptinezumab is a monoclonal antibody (mAb) that is administered as a quarterly 30-minute IV infusion. Eptinezumab was designed for immediate and complete bioavailability with high specificity and strong binding for suppression of calcitonin gene-related peptide (CGRP), a neuropeptide believed to play a key role in mediating and initiating migraines, it is the first IV CGRP therapy for migraine prevention.
Tarlige/Mirogabalin (Daiichi Sankyo)
Mirogabalin besylate/Tarlige is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia. The drug binds to and modulates the α2δ-1 subunit of the voltage-gated calcium channels widely found in the nervous system in areas that mediate pain transmission and processing. Mirogabalin has a unique binding profile and long duration of action. The drug was approved in Japan for the treatment of PNP in 2019.
Aimovig/Erenumab (Amgen/Novartis)
Aimovig (Erenumab), formerly known as AMG 334 is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high-affinity binding to the calcitonin gene-related peptide receptor (CGRP-R). Aimovig is an EMA and the US FDA-approved migraine prevention treatment designed specifically to block the CGRP-R, which plays a critical role in migraine.
Ajovy/Fremanezumab (Teva Pharmaceuticals)
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP), a 37–amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab targets both α and β isoforms of the CGRP ligand (not the receptor), has flexible dosing, and is administered through subcutaneous injection.
Note: Detailed Current therapies assessment will be provided in the full report of Chronic Pain
Chronic Pain Emerging Drugs
Tanezumab (Pfizer/Eli Lilly and Company)
Tanezumab is an investigational monoclonal antibody being developed by Pfizer and Eli Lilly and Company. It works by selectively targeting, binding to, and inhibiting NGF (nerve growth factor). NGF levels increase in the body as a result of injury, inflammation, or chronic pain states. By inhibiting NGF, tanezumab may help to keep pain signals produced by muscles, skin, and organs from reaching the spinal cord and brain. Tanezumab has a novel mechanism that acts in the periphery differently than opioids and other analgesics, including NSAIDs, and in studies to date, tanezumab has not demonstrated a risk of addiction, misuse, or dependence. In March 2020, Pfizer and Eli Lilly and Company announced that the US FDA accepted for review a Biologics License Application (BLA) for tanezumab for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics.
Fasinumab/REGN475 (Regeneron Pharmaceuticals/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation)
Fasinumab (REGN475) is an investigational fully human IgG4κ monoclonal antibody under development by Regeneron Pharmaceuticals, Teva Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation. It is designed to target nerve growth factor (NGF), a protein that plays a central role in the regulation of pain signaling. Blocking NGF may reduce chronic low back pain (CLBP). It is under development by Mitsubishi Tanabe, Regeneron, and Teva, as a collaboration on the global development and commercialization of fasinumab. It is an investigational NGF antibody in clinical development for osteoarthritis pain and chronic low back pain. It was invented by Regeneron Pharmaceuticals using the company's proprietary VelocImmune technology that yields optimized fully-human antibodies. There is evidence that NGF levels are elevated in the synovial fluid of patients with chronic pain conditions.
Atogepant (Allergan [acquired by ABBVie])
Atogepant is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist (Gepant). It is specifically being developed by Allergan, which has now been acquired by AbbVie, for the preventive treatment of migraines. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks and selective CGRP receptor antagonists confer clinical benefit in migraine.
Ampion (Ampio Pharmaceuticals)
Ampion is an investigational drug being developed by Ampio Pharmaceuticals. It is an intra-articular injection to treat the signs and symptoms of severe osteoarthritis of the knee (OAK). Ampion regulates key components of the immune response connected to pain, inflammation, and joint damage in osteoarthritis.
Ampion reduces the production of the cytokines responsible for inflammation (TNFα, IL-1β, IL-6, IL-12) by regulating with the genetic transcriptional pathways (NFκB, STAT) responsible for the overproduction of these cytokines while activating anti-inflammatory proteins responsible for tissue growth and healing. This mechanism of action has an overall clinical effect that has been shown to relieve pain and improve function in the knee for patients.
Rexlemestrocel/MPC-06-ID (Gruenthal/Mesoblast)
Rexlemestrocel, also known as Rexlemestrocel-L or MPC-06-ID is a late-stage development product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections, and have no further treatment option other than invasive and costly surgical interventions. MPCs have anti-inflammatory effects and secrete multiple paracrine factors that stimulate new proteoglycan and collagen synthesis by chondrocytes in vitro and by resident cells in the nucleus and annulus in vivo. MPCs have also been shown to produce anti-inflammation factors.
Note: Detailed emerging therapies assessment will be provided in the final report.
Chronic or persistent pain is pain that carries on for longer than 12 weeks despite medication or treatment. Most people get back to normal after pain following an injury or operation. But sometimes the pain carries on for longer or comes on without any history of an injury or operation. Chronic pain may be related to several different medical conditions including (but not limited to) diabetes, arthritis, migraine, fibromyalgia, cancer, sciatica, and previous trauma or injury.
Several types of medications are being used in the management of chronic pain, including acetaminophen, ibuprofen, aspirin, COX-2 inhibitors, antimigraine medications, sedatives, opioids, and antidepressants. Nonpharmacologic treatments for chronic pain can include exercise, physical therapy, counseling, electrical stimulation, biofeedback, acupuncture, hypnosis, chiropractic medicine, and other treatments. There are several approved drugs for the treatment of chronic pain such as Emgality (Galcanezumab), Savella (Milnacipran), Vyepti (Eptinezumab), Tarlige (Mirogabalin), Aimovig (Erenumab), and Ajovy (Fremanezumab).
Still, there are some unmet needs in the chronic pain market. There are various challenges in identifying biomarkers for chronic pain. Also, the mechanism-based diagnosis has not been feasible, as its pathophysiological components are not elucidated yet. Therefore, the current diagnosis of chronic pain is based solely on clinical signs and symptoms.
Nevertheless, recently some developmental initiatives have been taken towards the management of chronic pain. Several pharmaceutical key players have taken to the initiative to meet the unmet needs of the present situation of the chronic pain market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates.
Key players such as Centrexion Therapeutics (CNTX-4975), Pfizer and Eli Lilly and Company (Tanezumab), Regeneron, Teva Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation (Fasinumab), Sorrento Therapeutics (Resiniferatoxin), Taiwan Liposome Company (TLC599), Ampio Pharmaceuticals (Ampion), Samumed (Lorecivivint), Gruenthal and Mesoblast (MPC-06-ID), Biogen (BIIB074), Allergan (Atogepant) and several others are investigating their candidates for the management of chronic pain in the 7MM.
Key Findings
The Chronic Pain market size in the 7MM is expected to change during the study period 2018–2030. The therapeutic market of Chronic Pain in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 3.0%. According to the estimates, the highest market size of Chronic Pain is found in the United States followed by Japan.
The United States Market Outlook
The total market size of Chronic Pain therapies in the United States is expected to increase with a CAGR of 2.7% in the study period (2018–2030).
EU-5 Countries: Market Outlook
The total market size of Chronic Pain therapies in EU-5 countries is expected to increase with a CAGR of 3.2% in the study period (2018–2030).
Japan Market Outlook
The total market size of Chronic Pain therapies in Japan is expected to increase with a CAGR of 3.4% in the study period (2018–2030).
The drugs which are in pipeline include:
1. Tanezumab (Pfizer/Eli Lilly and Company)
2. Fasinumab/REGN475 (Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation)
3. Atogepant (Allergan [acquired by ABBVie])
4. STA363 (Stayble Therapeutics)
5. NYX-2925 (Aptinyx)
6. LAT8881 (Lateral Pharma)
7. LY-3451838 (Eli Lilly and Company)
8. Lorecivivint/SM04690 (Samumed)
9. Resiniferatoxin/MCP-101 (Sorrento Therapeutics)
10. Ampion (Ampio Pharmaceuticals)
11. SP-102/Semdexa (Semnur Pharmaceuticals)
12. CAM2038 (Braeburn Pharmaceuticals/Camurus)
13. TLC599 (Taiwan Liposome Company)
14. CNTX-4975 (Centrexion Therapeutics)
15. Vixotrigine/BIIB074 (Biogen)
16. ALLOD-2 (Allodynic Therapeutics)
17. LX9211 (Lexicon Pharmaceuticals)
18. LY3556050 (Eli Lilly and Company)
19. Rexlemestrocel/MPC-06-ID (Gruenthal/Mesoblast)
20. LY3016859 (Eli Lilly and Company)
21. Ricolinostat/ACY-1215 (Regenacy Pharmaceuticals)
22. AP-325 (Algiax Pharmaceuticals)
23. BAY1817080/Eliapixant (Bayer)
24. VX-150 (Vertex Pharmaceuticals)
25. Omnitram/Desmetramadol (Syntrix Biosystems)
26. NFX88 (Neurofix Pharma)
27. AminoFix/dHACM (MiMedx)
Note: Detailed emerging therapies assessment will be provided in the final report.
A hospital-based fee plan offers the highest degree of reimbursement in most cases. However, locating the pain center on the campus of the hospital is not the only option. According to Centers for Medicare and Medicaid Services (CMS) rules, whether it is within 35 miles of the hospital itself and satisfies other criteria that generally involve the center functioning under the hospital’s license, an offsite facility may be refunded under the hospital-based fee schedule.
Access to pain relief facilities is highly inconsistent at present, both within and across countries in Europe. Also, the level of care offered by available pain health facilities differs. For all people with chronic pain in Europe, a new minimum standard of care is needed.
It is worth noting that patients often experience obstacles related to almost absent or inadequate insurance coverage and reimbursement for pain management services for the persistent pain. There is a lack of consistency in insurance coverage and a lack of coverage alignment with current practice guidelines for pain management. Recently, the Health and Human Services National Pain Strategy called for prominent coverage for pain management services. This is especially valid for nonpharmacologic and behavioral health interventions.
Additionally, the reimbursement system does not facilitate lifestyle counseling, nor does it align with encouraging prevention. It is not conducive to treating chronic pain optimally and prescribing opioids safely. The whole process of chronic pain treatment and safe-opioid practices takes time, and currently, providers lack adequate time. Given that explaining physical therapy, cognitive behavioral therapy, and other medicines can take significantly more time than writing an opioid prescription, it is very likely that the current reimbursement system and the time constraints it has fostered have contributed to the over-prescription of opioids.
Teva Pharmaceuticals offer a savings program for Ajoy (fremanezumab-vfrm). Eligible patients can use the Savings Offer for Ajoy, which may cost as little as USD 5 for each prescription. Patients can take the Savings Offer and pharmacist instructions to the pharmacy. Also, Aimovig Ally Access Card offers eligible commercially insured patients to pay as little as USD 5 per month per the prescription of Aimovig with a maximum benefit of USD 3500 annually, and to remain eligible in the program patient must re-enroll every 12 months. This applies to patient out-of-pocket costs, including deductible, co-insurance, and copayments for Aimovig. Also, if the patient’s health plan does not cover Aimovig or requires prior authorization, the patient can qualify for the Bridge to Commercial Coverage Offer and receive Aimovig free for up to 3 doses, while pursuing approval from their health plan.
Note: Detailed HTA assessment will be provided in the final report.
To keep up with current market trends, we take KOLs' and SMEs ’ opinions working in the Chronic Pain domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Pain market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Chronic Pain Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Report Introduction
3. Chronic Pain Market Overview at a Glance
3.1. Market Share (%) Distribution of Chronic Pain in 2018
3.2. Market Share (%) Distribution of Chronic Pain in 2030
4. Executive Summary of Chronic Pain
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Types of Chronic Pain
6.2.1. Neuropathic Pain
6.2.2. Arthritis Pain
6.2.3. Cancer Pain
6.2.4. Fibromyalgia
6.2.5. Migraine
6.2.6. Chronic Low Back Pain (CLBP)
6.2.7. Postsurgical pain
6.3. Signs and symptoms of Chronic Pain
6.3.1. Symptoms of Fibromyalgia
6.3.2. Symptoms of Neuropathic Pain
6.3.3. Symptoms of Postsurgical Pain
6.3.4. Symptoms of Cancer Pain
6.3.5. Symptoms of Migraine
6.3.6. Symptoms of Arthritis Pain
6.4. Risk factors and causes of Chronic Pain
6.5. Pathophysiology of Chronic Pain
6.6. Genetics of Chronic Pain
6.7. Complications of Chronic Pain
7. Diagnosis of Chronic Pain
7.1. Physical, Neurological and Mental health exams
7.2. Blood tests and Urine Analysis
7.3. Imaging tests
7.3.1. X-Rays
7.3.2. Bone scan
7.3.3. Computed Tomography (CT) imaging
7.3.4. Magnetic Resonance Imaging
7.3.5. Myelogram
7.4. Nerve Tests
7.4.1. Electromyography (EMG)
7.4.2. Nerve Conduction Study
7.5. Differential Diagnosis
7.6. Diagnostic Guidelines
7.6.1. American Family Physician – Peripheral Neuropathy guidelines
7.6.2. NICE Guidelines for Lower Back Pain and Sciatica
7.6.3. American Pain Society – Guidelines for Postoperative Pain
7.6.4. Guidelines for clinical diagnosis of fibromyalgia
7.6.5. Diagnostic Guidelines from American Society of Anesthesiologists Task Force
8. Current Treatment
8.1. Treatment Algorithm
8.2. Neuropathic Pain
8.3. Rheumatoid Arthritis (RA)
8.4. Osteoarthritis (OA)
8.5. Fibromyalgia
8.6. Advanced Cancer Pain
8.7. Chronic Migraine Pain
8.8. Chronic Back Pain
8.9. Postsurgical Pain
8.10. Treatment Guidelines
8.10.1. Center for Disease Control and Prevention (CDC) Guidelines
8.10.2. American College of Physicians (ACP) Guidelines
8.10.3. NICE Guidelines
8.10.4. American Society of Anesthesiologists Task Force on Chronic Pain Management
8.10.5. WHO Pain Ladder for Advanced Cancer Pain
8.10.6. ESMO Clinical Practice Guidelines
8.10.7. Spanish Guidelines
8.10.8. Department of Veterans Af airs and the Department of Defense (VA/DoD) clinical practice guideline for opioid therapy for chronic pain
8.10.9. European Pain Federation guidelines on appropriate opioid use in chronic pain management
8.10.10. Guideline of the Japanese Society of Palliative Medicine for Pharmacological Management of Cancer Pain
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Epidemiology of Chronic Pain
9.3. Epidemiology Scenario: 7MM
9.3.1. Total Prevalent Cases of Chronic Pain
9.3.2. Total Diagnosed Cases of Chronic Pain
9.3.3. Total Age-specific Cases of Chronic Pain
9.3.4. Cause-specific Cases of Chronic Pain
9.3.5. Severity-specific Cases of Chronic Pain
9.3.6. Total Treated Cases of Chronic Pain
10. The United States
10.1. Total Prevalent Cases of Chronic Pain
10.2. Total Diagnosed Cases of Chronic Pain
10.3. Total Age-specific Cases of Chronic Pain
10.4. Cause-specific Cases of Chronic Pain
10.5. Severity-specific Cases of Chronic Pain
10.6. Total Treated Cases of Chronic Pain
11. EU-5
11.1. Germany
11.1.1. Total Prevalent Cases of Chronic Pain
11.1.2. Total Diagnosed Cases of Chronic Pain
11.1.3. Total Age-specific Cases of Chronic Pain
11.1.4. Cause-specific Cases of Chronic Pain
11.1.5. Severity-specific Cases of Chronic Pain
11.1.6. Total Treated Cases of Chronic Pain
11.2. France
11.2.1. Total Prevalent Cases of Chronic Pain
11.2.2. Total Diagnosed Cases of Chronic Pain
11.2.3. Total Age-specific Cases of Chronic Pain
11.2.4. Cause-specific Cases of Chronic Pain
11.2.5. Severity-specific Cases of Chronic Pain
11.2.6. Total Treated Cases of Chronic Pain
11.3. Italy
11.3.1. Total Prevalent Cases of Chronic Pain
11.3.2. Total Diagnosed Cases of Chronic Pain
11.3.3. Total Age-specific Cases of Chronic Pain
11.3.4. Cause-specific Cases of Chronic Pain
11.3.5. Severity-specific Cases of Chronic Pain
11.3.6. Total Treated Cases of Chronic Pain
11.4. Spain
11.4.1. Total Prevalent Cases of Chronic Pain
11.4.2. Total Diagnosed Cases of Chronic Pain
11.4.3. Total Age-specific Cases of Chronic Pain
11.4.4. Cause-specific Cases of Chronic Pain
11.4.5. Severity-specific Cases of Chronic Pain
11.4.6. Total Treated Cases of Chronic Pain
11.5. The United Kingdom
11.5.1. Total Prevalent Cases of Chronic Pain
11.5.2. Total Diagnosed Cases of Chronic Pain
11.5.3. Total Age-specific Cases of Chronic Pain
11.5.4. Cause-specific Cases of Chronic Pain
11.5.5. Severity-specific Cases of Chronic Pain
11.5.6. Total Treated Cases of Chronic Pain
12. Japan
12.1.1. Total Prevalent Cases of Chronic Pain
12.1.2. Total Diagnosed Cases of Chronic Pain
12.1.3. Total Age-specific Cases of Chronic Pain
12.1.4. Cause-specific Cases of Chronic Pain
12.1.5. Severity-specific Cases of Chronic Pain
12.1.6. Total Treated Cases of Chronic Pain
13. Patient Journey
14. Key Endpoints in Chronic Pain Clinical Trials
15. Marketed Therapies
15.1. Emgality (Galcanezumab): Elli Lilly and Company
15.1.1. Drug Description
15.1.2. Regulatory Milestones
15.1.3. Other Developmental Activities
15.1.4. Pivotal Clinical Trial
15.1.5. Ongoing Current Pipeline Activity
15.2. Savella (Milnacipran): Allergan (acquired by AbbVie)
15.2.1. Drug Description
15.2.2. Regulatory Milestones
15.2.3. Other Developmental Activities
15.2.4. Pivotal Clinical Trial
15.3. Vyepti (Eptinezumab): Alder Biopharmaceuticals (Acquired by Lundbeck)
15.3.1. Product Description
15.3.2. Regulatory Milestones
15.3.3. Other Developmental Activities
15.3.4. Pivotal Clinical Trial
15.4. Tarlige (Mirogabalin): Daiichi Sankyo
15.4.1. Product Description
15.4.2. Regulatory Milestones
15.4.3. Other Developmental Activities
15.4.4. Pivotal Clinical Trial
15.5. Aimovig (Erenumab): Amgen/Novartis
15.5.1. Product Profile
15.5.2. Regulatory Milestones
15.5.3. Other Developmental Activities
15.5.4. Pivotal Clinical Trials
15.5.5. Ongoing Current Pipeline Activity
15.6. Ajovy (Fremanezumab): Teva Pharmaceuticals
15.6.1. Product Description
15.6.2. Regulatory Milestones
15.6.3. Other Developmental Activities
15.6.4. Pivotal Clinical Trials
16. Emerging Therapies
16.1. Tanezumab: Pfizer and Eli Lilly and Company
16.1.1. Drug Description
16.1.2. Other Developmental Activities
16.1.3. Clinical Development
16.1.4. Safety and Efficacy
16.2. Fasinumab (MT-5547, REGN475, SAR164877): Regeneron, Teva Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation
16.2.1. Drug Description
16.2.2. Other Developmental Activities
16.2.3. Clinical Development
16.2.4. Safety and Efficacy
16.3. Atogepant: Allergan (acquired by ABBVie)
16.3.1. Drug Description
16.3.2. Other Developmental Activities
16.3.3. Clinical Development
16.4. STA363: Stayble Therapeutics
16.4.1. Drug Description
16.4.2. Other Developmental Activities
16.4.3. Clinical Development
16.4.4. Safety and Efficacy
16.5. NYX-2925: Aptinyx
16.5.1. Drug Description
16.5.2. Other Developmental Activities
16.5.3. Clinical Development
16.5.4. Safety and Efficacy
16.6. LAT8881: Lateral Pharma
16.6.1. Drug Description
16.6.2. Other Developmental Activities
16.6.3. Clinical Development
16.7. LY-3451838: Eli Lilly and Company
16.7.1. Drug Description
16.7.2. Clinical Development
16.8. Lorecivivint (SM04690): Samumed
16.8.1. Drug Description
16.8.2. Other Developmental Activities
16.8.3. Clinical Development
16.8.4. Safety and Efficacy
16.9. RTX (MCP-101; Resiniferatoxin): Sorrento Therapeutics
16.9.1. Product Description
16.9.2. Other Developmental Activities
16.9.3. Clinical Development
16.9.4. Safety and Efficacy
16.10. Ampion: Ampio Pharmaceuticals
16.10.1. Product Description
16.10.2. Other Developmental Activities
16.10.3. Clinical Development
16.10.4. Safety and Efficacy
16.11. SP-102 (Semdexa): Semnur Pharmaceuticals
16.11.1. Product Description
16.11.2. Other Developmental Activities
16.11.3. Clinical Development
16.11.4. Safety and Efficacy
16.12. CAM2038: Braeburn Pharmaceuticals and Camurus
16.12.1. Drug Description
16.12.2. Other Developmental Activities
16.12.3. Clinical Development
16.12.4. Safety and Efficacy
16.13. TLC599: Taiwan Liposome Company
16.13.1. Product Description
16.13.2. Other Developmental Activities
16.13.3. Clinical Development
16.14. CNTX-4975: Centrexion Therapeutics
16.14.1. Product Description
16.14.2. Other Developmental Activities
16.14.3. Clinical Development
16.14.4. Safety and Efficacy
16.15. Vixotrigine (BIIB074): Biogen
16.15.1. Drug Description
16.15.2. Other Developmental Activities
16.15.3. Clinical Development
16.15.4. Safety and Efficacy
16.16. ALLOD-2: Allodynic Therapeutics
16.16.1. Product Description
16.16.2. Other Developmental Activities
16.16.3. Clinical Development
16.17. LX9211: Lexicon Pharmaceuticals
16.17.1. Product Description
16.17.2. Other Developmental Activities
16.17.3. Clinical Development
16.17.4. Safety and Efficacy
16.18. LY3556050: Eli Lilly and Company
16.18.1. Product Description
16.18.2. Clinical Development
16.19. Rexlemestrocel (MPC-06-ID): Gruenthal and Mesoblast
16.19.1. Product Description
16.19.2. Other Developmental Activities
16.19.3. Clinical Development
16.19.4. Safety and Efficacy
16.20. LY3016859: Eli Lilly and Company
16.20.1. Drug Description
16.20.2. Clinical Development
16.20.3. Safety and Efficacy
16.21. Ricolinostat (ACY-1215): Regenacy Pharmaceuticals
16.21.1. Drug Description
16.21.2. Other Developmental Activities
16.21.3. Clinical Development
16.22. AP-325: Algiax Pharmaceuticals
16.22.1. Product Description
16.22.2. Other Developmental Activities
16.22.3. Clinical Development
16.23. BAY1817080 (Eliapixant): Bayer
16.23.1. Product Description
16.23.2. Clinical Development
16.24. VX-150: Vertex Pharmaceuticals
16.24.1. Product Description
16.24.2. Clinical Development
16.24.3. Safety and Efficacy
16.25. Omnitram (Desmetramadol): Syntrix Biosystems
16.25.1. Drug Description
16.25.2. Other Developmental Activities
16.25.3. Clinical Development
16.26. NFX88: Neurofix Pharma
16.26.1. Drug Description
16.26.2. Other Developmental Activities
16.26.3. Clinical Development
16.27. AminoFix (dHACM): MiMedx
16.27.1. Drug Description
16.27.2. Other Developmental Activities
16.27.3. Clinical Development
17. Chronic Pain: 7 Major Market Analysis
17.1. Key Findings
17.2. Market Outlook
17.3. 7MM Market Size
17.3.1. Total Market Size of Chronic Pain in the 7MM
17.3.2. Market Size of Chronic Pain by Therapies in the 7MM
18. The United States Market Size
18.1. Total Market Size of Chronic Pain in the United States
18.2. Market Size of Chronic Pain by Therapies in the United States
19. EU-5 Market Size
19.1. Germany
19.1.1. Total Market size of Chronic Pain in Germany
19.1.2. Market Size of Chronic Pain by Therapies in Germany
19.2. France
19.2.1. Total Market size of Chronic Pain in France
19.2.2. Market Size of Chronic Pain by Therapies in France
19.3. Italy
19.3.1. Total Market size of Chronic Pain in Italy
19.3.2. Market Size of Chronic Pain by Therapies in Italy
19.4. Spain
19.4.1. Total Market size of Chronic Pain in Spain
19.4.2. Market Size of Chronic Pain by Therapies in Spain
19.5. The United Kingdom
19.5.1. Total Market size of Chronic Pain in the United Kingdom
19.5.2. Market Size of Chronic Pain by Therapies in the United Kingdom
20. Japan
20.1. Total Market size of Chronic Pain in Japan
20.2. Market Size of Chronic Pain by Therapies in Japan
21. Market Access and Reimbursement
21.1. Key HTA decisions for Chronic Pain
21.2. Patient Access Programs
22. Market Drivers
23. Market Barriers
24. SWOT Analysis
25. Unmet Needs
26. Appendix
26.1. Bibliography
26.2. Report Methodology
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight
List of Table
Table 1: Summary of Chronic Pain, Market, Epidemiology, and Key Events (2018–2030)
Table 2: Pain classifications
Table 3: Genes reported in genetic association studies of chronic pain conditions
Table 4: Diagnostic Guidelines
Table 5: Diagnostic Guidelines
Table 6: Diagnostic Guidelines
Table 7: Preventive measures
Table 8: Pharmacological treatments for pain
Table 9: WHO pain ladder
Table 10: Total Prevalent Cases of Chronic Pain in the 7MM (2018–2030)
Table 11: Total Diagnosed Cases of Chronic Pain in the 7MM (2018–2030)
Table 12: Total Age-specific Cases of Chronic Pain in the 7MM (2018–2030)
Table 13: Cause-specific Cases of Chronic Pain in the 7MM (2018–2030)
Table 14: Severity-specific Cases of Chronic Pain in the 7MM (2018–2030)
Table 15: Total Treated Cases of Chronic Pain in the 7MM (2018–2030)
Table 16: Total Prevalent Cases of Chronic Pain in the United States (2018–2030)
Table 17: Total Diagnosed Cases of Chronic Pain in the United States (2018–2030)
Table 18: Total Age-specific Cases of Chronic Pain in the United States (2018–2030)
Table 19: Cause-specific Cases of Chronic Pain in the United States (2018–2030)
Table 20: Severity-specific Cases of Chronic Pain in the United States (2018–2030)
Table 21: Total Treated Cases of Chronic Pain in the United States (2018–2030)
Table 22: Total Prevalent Cases of Chronic Pain in Germany (2018–2030)
Table 23: Total Diagnosed Cases of Chronic Pain in Germany (2018–2030)
Table 24: Total Age-specific Cases of Chronic Pain in Germany (2018–2030)
Table 25: Cause-specific Cases of Chronic Pain in Germany (2018–2030)
Table 26: Severity-specific Cases of Chronic Pain in Germany (2018–2030)
Table 27: Total Treated Cases of Chronic Pain in Germany (2018–2030)
Table 28: Total Prevalent Cases of Chronic Pain in France (2018–2030)
Table 29: Total Diagnosed Cases of Chronic Pain in France (2018–2030)
Table 30: Total Age-specific Cases of Chronic Pain in France (2018–2030)
Table 31: Cause-specific Cases of Chronic Pain in France (2018–2030)
Table 32: Severity-specific Cases of Chronic Pain in France (2018–2030)
Table 33: Total Treated Cases of Chronic Pain in France (2018–2030)
Table 34: Total Prevalent Cases of Chronic Pain in Italy (2018–2030)
Table 35: Total Diagnosed Cases of Chronic Pain in Italy (2018–2030)
Table 36: Total Age-specific Cases of Chronic Pain in Italy (2018–2030)
Table 37: Cause-specific Cases of Chronic Pain in Italy (2018–2030)
Table 38: Severity-specific Cases of Chronic Pain in Italy (2018–2030)
Table 39: Total Treated Cases of Chronic Pain in Italy (2018–2030)
Table 40: Total Prevalent Cases of Chronic Pain in Spain (2018–2030)
Table 41: Total Diagnosed Cases of Chronic Pain in Spain (2018–2030)
Table 42: Total Age-specific Cases of Chronic Pain in Spain (2018–2030)
Table 43: Cause-specific Cases of Chronic Pain in Spain (2018–2030)
Table 44: Severity-specific Cases of Chronic Pain in Spain (2018–2030)
Table 45: Total Treated Cases of Chronic Pain in Spain (2018–2030)
Table 46: Total Prevalent Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 47: Total Diagnosed Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 48: Total Age-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 49: Cause-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 50: Severity-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 51: Total Treated Cases of Chronic Pain in the United Kingdom (2018–2030)
Table 52: Total Prevalent Cases of Chronic Pain in Japan (2018–2030)
Table 53: Total Diagnosed Cases of Chronic Pain in Japan (2018–2030)
Table 54: Total Age-specific Cases of Chronic Pain in Japan (2018–2030)
Table 55: Cause-specific Cases of Chronic Pain in Japan (2018–2030)
Table 56: Severity-specific Cases of Chronic Pain in Japan (2018–2030)
Table 57: Total Treated Cases of Chronic Pain in Japan (2018–2030)
Table 58: Oswestry Disability Index
Table 59: Galcanezumab, Clinical Trial Description, 2021
Table 60: Aimvoig, Clinical Trial Description, 2021
Table 61: Tanezumab, Clinical Trial Description, 2021
Table 62: Fasinumab, Clinical Trial Description, 2021
Table 63: Atogepant, Clinical Trial Description, 2021
Table 64: STA363, Clinical Trial Description, 2021
Table 65: NYX-2925, Clinical Trial Description, 2021
Table 66: LAT8881, Clinical Trial Description, 2021
Table 67: LY-3451838, Clinical Trial Description, 2021
Table 68: Lorecivivint (SM04690), Clinical Trial Description, 2021
Table 69: RTX (MCP-101; Resinferatoxin),Clinical Trial Description, 2021
Table 70: Ampion, Clinical Trial Description, 2021
Table 71: SP-102, Clinical Trial Description, 2021
Table 72: CAM2038, Clinical Trial Description, 2021
Table 73: TLC599, Clinical Trial Description, 2021
Table 74: CNTX-4975, Clinical Trial Description, 2021
Table 75: BIIB074, Clinical Trial Description, 2021
Table 76: ALLOD-2, Clinical Trial Description, 2021
Table 77: LX9211, Clinical Trial Description, 2021
Table 78: LY3556050,Clinical Trial Description, 2021
Table 79: Rexlemestrocel (MPC-06-ID),Clinical Trial Description, 2021
Table 80: LY3016859, Clinical Trial Description, 2021
Table 81: Ricolinostat (ACY-1215), Clinical Trial Description, 2021
Table 82: AP-325Clinical Trial Description, 2021
Table 83: BAY1817080, Clinical Trial Description, 2021
Table 84: VX-150, Clinical Trial Description, 2021
Table 85: Patents for Omnitram
Table 86: Omnitram, Clinical Trial Description, 2021
Table 87: NFX88, Clinical Trial Description, 2021
Table 88: Patents for AmnioFix
Table 89: AmnioFix, Clinical Trial Description, 2021
Table 90: 7MM Market Size of Chronic Pain in USD Million (2018–2030)
Table 91: 7MM Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 92: The United States Market Size of Chronic Pain in USD Million (2018–2030)
Table 93: The United States Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 94: Germany Market Size of Chronic Pain in USD Million (2018–2030)
Table 95: Germany Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 96: France Market Size of Chronic Pain in USD Million (2018–2030)
Table 97: France Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 98: Italy Market Size of Chronic Pain in USD Million (2018–2030)
Table 99: Italy Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 100: Spain Market Size of Chronic Pain in USD Million (2018–2030)
Table 101: Spain Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 102: The United Kingdom Market Size of Chronic Pain in USD Million (2018–2030)
Table 103: The United Kingdom Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 104: Japan Market Size of Chronic Pain in USD Million (2018–2030)
Table 105: Japan Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Table 106: Key HTA Decisions for Chronic Pain
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Understanding Chronic pain
Figure 3: Mechanism of postsurgical pain
Figure 4: Risk factors of Chronic Pain
Figure 5: Pathophysiology of chronic pain
Figure 6: Managing Chronic Pain in Adults
Figure 7: World Health Organization (WHO) analgesic Ladder
Figure 8: Total Prevalent Cases of Chronic Pain in the 7MM (2018–2030)
Figure 9: Total Diagnosed Cases of Chronic Pain in the 7MM (2018–2030)
Figure 10: Total Age-specific Cases of Chronic Pain in the 7MM (2018–2030)
Figure 11: Cause-specific Cases of Chronic Pain in the 7MM (2018–2030)
Figure 12: Severity-specific Cases of Chronic Pain in the 7MM (2018–2030)
Figure 13: Total Treated Cases of Chronic Pain in the 7MM (2018–2030)
Figure 14: Total Prevalent Cases of Chronic Pain in the United States (2018–2030)
Figure 15: Total Diagnosed Cases of Chronic Pain in the United States (2018–2030)
Figure 16: Total Age-specific Cases of Chronic Pain in the United States (2018–2030)
Figure 17: Cause-specific Cases of Chronic Pain in the United States (2018–2030)
Figure 18: Severity-specific Cases of Chronic Pain in the United States (2018–2030)
Figure 19: Total Treated Cases of Chronic Pain in the United States (2018–2030)
Figure 20: Total Prevalent Cases of Chronic Pain in Germany (2018–2030)
Figure 21: Total Diagnosed Cases of Chronic Pain in Germany (2018–2030)
Figure 22: Total Age-specific Cases of Chronic Pain in Germany (2018–2030)
Figure 23: Cause-specific Cases of Chronic Pain in Germany (2018–2030)
Figure 24: Severity-specific Cases of Chronic Pain in Germany (2018–2030)
Figure 25: Total Treated Cases of Chronic Pain in Germany (2018–2030)
Figure 26: Total Prevalent Cases of Chronic Pain in France (2018–2030)
Figure 27: Total Diagnosed Cases of Chronic Pain in France (2018–2030)
Figure 28: Total Age-specific Cases of Chronic Pain in France (2018–2030)
Figure 29: Cause-specific Cases of Chronic Pain in France (2018–2030)
Figure 30: Severity-specific Cases of Chronic Pain in France (2018–2030)
Figure 31: Total Treated Cases of Chronic Pain in France (2018–2030)
Figure 32: Total Prevalent Cases of Chronic Pain in Italy (2018–2030)
Figure 33: Total Diagnosed Cases of Chronic Pain in Italy (2018–2030)
Figure 34: Total Age-specific Cases of Chronic Pain in Italy (2018–2030)
Figure 35: Cause-specific Cases of Chronic Pain in Italy (2018–2030)
Figure 36: Severity-specific Cases of Chronic Pain in Italy (2018–2030)
Figure 37: Total Treated Cases of Chronic Pain in Italy (2018–2030)
Figure 38: Total Prevalent Cases of Chronic Pain in Spain (2018–2030)
Figure 39: Total Diagnosed Cases of Chronic Pain in Spain (2018–2030)
Figure 40: Total Age-specific Cases of Chronic Pain in Spain (2018–2030)
Figure 41: Cause-specific Cases of Chronic Pain in Spain (2018–2030)
Figure 42: Severity-specific Cases of Chronic Pain in Spain (2018–2030)
Figure 43: Total Treated Cases of Chronic Pain in Spain (2018–2030)
Figure 44: Total Prevalent Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 45: Total Diagnosed Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 46: Total Age-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 47: Cause-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 48: Severity-specific Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 49: Total Treated Cases of Chronic Pain in the United Kingdom (2018–2030)
Figure 50: Total Prevalent Cases of Chronic Pain in Japan (2018–2030)
Figure 51: Total Diagnosed Cases of Chronic Pain in Japan (2018–2030)
Figure 52: Total Age-specific Cases of Chronic Pain in Japan (2018–2030)
Figure 53: Cause-specific Cases of Chronic Pain in Japan (2018–2030)
Figure 54: Severity-specific Cases of Chronic Pain in Japan (2018–2030)
Figure 55: Total Treated Cases of Chronic Pain in Japan (2018–2030)
Figure 56: Mechanism of action of Fasinumab
Figure 57: Mechanism of action of Lorecivivint
Figure 58: Mechanism of action of Ampion
Figure 59: Mechanism of action of Desmetramadol
Figure 60: Market Size of Chronic Pain in the 7MM, USD Million (2018–2030)
Figure 61: 7MM Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 62: Market Size of Chronic Pain in the United States, USD Million (2018–2030)
Figure 63: The United States Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 64: Market Size of Chronic Pain in Germany, USD Million (2018–2030)
Figure 65: Germany Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 66: Market Size of Chronic Pain in France, USD Million (2018–2030)
Figure 67: France Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 68: Market Size of Chronic Pain in Italy, USD Million (2018–2030)
Figure 69: Italy Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 70: Market Size of Chronic Pain in Spain, USD Million (2018–2030)
Figure 71: Spain Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 72: Market Size of Chronic Pain in the United Kingdom, USD Million (2018–2030)
Figure 73: The United Kingdom Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 74: Market Size of Chronic Pain in Japan, USD Million (2018–2030)
Figure 75: Japan Market Size of Chronic Pain by Therapies in USD Million (2018–2030)
Figure 76: Market Drivers
Figure 77: Market Barrier
